Schlumberger NV vs Viatris Inc — how do they compare? Schlumberger NV trades at $48.97 (market cap $72.69B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Schlumberger NV is far larger — about 3.6× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Schlumberger NV for 99 Days and Viatris Inc for 57 Days on average.
| SLB | VTRS | |
|---|---|---|
Market Cap | $72.69B | $20.03B |
Volume | 16,228,451 | 14,109,977 |
Sector | Energy | Health |
52-Week High | $60.10 | $18.27 |
52-Week Low | $31.72 | $9.74 |
Typical Hold Time | 99 Days | 57 Days |
Enterprise Value | $81.42B | $32.15B |
Dividend Yield | 2.41% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
SLB trades at $47.96, down 4.08% in the last session, with technical indicators showing bearish momentum. The company maintains strong fundamentals with consistent earnings beats and a robust $35.71B revenue base, though 2025 net income declined to $3.37B. Recent contract wins in Saudi Arabia, Oman, and Mozambique provide multi-year revenue visibility, supporting analyst optimism with an 84.85% buy rating and $64.58 consensus price target.
SLB presents a compelling value opportunity with significant upside to analyst targets, driven by expanding international contracts and solid cash flow generation. Key risks include oil price volatility and execution challenges in new projects. The stock's current technical weakness may offer an attractive entry point for long-term investors seeking energy sector exposure.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →